ImmuPharma PLC (LSE:IMM) has provided an update on its ongoing discussions with multiple prospective partners for P140, its lead autoimmune therapy candidate. The company is in active engagement with several major global pharmaceutical groups, seeking a partnership structure that aligns with its long-term strategy and maximizes shareholder value. While the original goal was to finalize an agreement by the end of 2025, ImmuPharma has extended the timetable into 2026 to ensure it secures the most advantageous deal.
The company emphasized that its financial footing remains solid, with a cash runway stretching into Q4 2026, strengthened by recent R&D tax credits and disciplined financial management. Leadership notes that the extra time affords the opportunity to pursue a partnership that fully supports P140’s commercial and clinical potential.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company dedicated to developing peptide-based therapies. Its pipeline includes innovative candidates targeting autoimmune disorders alongside a range of anti-infective treatments.
Leave a Reply